On September 21, "The Lancet-Psychiatry" published an epidemiological study on the prevalence of depression and the utilization of health services in China led by Professor Huang Yueqin of Peking University Sixth Hospital
It is reported that the study was part of the China Mental Health Survey from 2012 to 2015, aiming to provide the socio-economic factors related to depression and the current status of health service utilization for depression
Data show that in China, depression is the second most common disease among all diseases
In view of this, the Chinese Mental Health Survey adopted a multi-stage probability sampling method to select 157 nationally representative disease surveillance sites from 31 provinces in China, and completed the epidemiology of the cross-section of mental disorders in Chinese adults (≥18 years of age) In the survey, a total of 28140 respondents (12,537 males accounted for 44.
The investigators received standardized training and used the International Diagnostic Interview Questionnaire 3.
At the same time, the SDS Sheehan Disability Scale (SDS) was used to assess the dysfunction caused by the symptoms of depression in the past 12 months
The results of the study show that among all types of depression, the prevalence of women is higher than that of men (lifetime prevalence ratio is 1.
Among the 744 people diagnosed with depression in the past 12 months, 574 (75.
It is particularly worth noting that out of a total of 1,007 respondents who were diagnosed with depression in the past 12 months, only 84 (9.
Researchers believe that the country should formulate plans to increase the availability, accessibility and acceptability of health resources in order to improve the utilization of health services for people with depression
Related paper information: https://doi.
https://doi.
org/10.
1016/S2215-0366(21)00251-0
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
![9-[1,1'-biphenyl]-4-yl-3,3'-Bi-9H-carbazole](https://file.echemi.com/fileManage/upload/category/ac71ac0d-8ef6-11ec-89e5-fa163ed06441.png)
